tuftsin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Daly, M.M.; Mirsky, A.E. (January 1955). "Histones With High Lysine Content". Journal of General Physiology. 38 (3): 405–413. doi:10.1085/jgp.38.3.405. PMC 2147486. PMID 13221780. Allfrey, V.G.; Daly, M.M.; Mirsky, A.E. (January 20, 1955). "Some Observations on Protein Metabolism in Chromosomes of Non-Dividing Cells" (PDF). Journal of General Physiology. 38 (3): 415–424. doi:10.1085/jgp.38.3.415. PMC 2147482. PMID 13221781. Daly, M.M.; Allfrey, V.G.; Mirsky, A.E. (November 20, 1955). "Synthesis of Protein in the Pancreas. III. Uptake of Glycine-N15 by the Trypsinogen and Chymotrypsinogen of Mouse Pancreas" (PDF). Journal of General Physiology. 39 (2): 207–210. doi:10.1085/jgp.39.2.207. PMC 2147525. PMID 13271721. Deming, Q.B.; Mosbach, E.H.; Bevans, M.; Daly, M.M.; Abell, L.L.; Martin, E.; Brun, L.M.; Halpern, E.; Kaplan, R. (April 1, 1958). "Blood Pressure, Cholesterol Content of Serum and Tissues and Atherogenesis in the Rat" (PDF). The Journal of Experimental Medicine. 107 (4): 581–598. doi:10.1084/jem.107.4.581. PMC 2136835. PMID 13513919. Daly, Marie M.; Gupride, E. Gambetta (February 1, 1959). "The Respiration and Cytochrome Oxidase Activity of Rat Aorta in Experimental Hypertension" (PDF). Journal of Experimental Medicine. 109 (2): 187–195. doi:10.1084/jem.109.2.187. PMC 2136939. PMID 13620848. Adel, Harold; Daly, Marie M.; Deming, Quentin B.; Brun, Lili; Raeff, Victoria (1962). "Effect of Hypertension on Cholesterol Synthesis in Rats" (PDF).
== Mixed martial arts == In 2009, Pudzianowski signed a contract with Konfrontacja Sztuk Walki – a Polish mixed martial arts organization – to take part in four fights. He debuted as a mixed martial arts fighter on 11 December 2009, during the KSW 12 event in Warsaw, Poland, winning against Marcin Najman. Pudzianowski started throwing low kicks soon after the fight began. After several hits, Najman fell to the mat and Pudzianowski started delivering punches (a tactic known as ground-and-pound). Najman was forced to tap the mat, indicating he wanted to end the fight, which lasted for only 43 seconds. Pudzianowski collected 200,000 zlotys (US$70,000) for the fight. On 7 May 2010, during the KSW 13 event, Pudzianowski won his second fight, against Yusuke Kawaguchi. The fight lasted two full rounds, with Pudzianowski winning by judges' decision. The fight was described as a "sloppy brawl". It was noted Pudzianowski had control over most of the fight, but was "neutralized" by Kawaguchi, and that, by the second round, he was looking "to be out of energy and breathing heavily". On 21 May 2010, Pudzianowski went on to participate in the Moosin: God of Martial Arts event, where he fought former two time UFC Heavyweight Champion Tim Sylvia. Pudzianowski fractured his metatarsus during the first round and then went on to deplete his stamina during the rest of the fight, which ultimately led to Sylvia defeating him via submission at 1:43 of round 2.
=== Aging === The Elaunin fibers and other parts of the elastic system undergo changes as tissues age. The elaunin fibers slowly start to lose strength and flexibility which normally helps keep our tissues resilient. By the time a person reaches middle age, the fibers show signs of breaking down; this is part of the normal aging process, even for individuals who protect their skin from sun exposure. In sun-exposed skin, the elaunin fibers are affected more, which causes deterioration to occur faster and the fibers to weaken more intensely. Over time sun-exposed skin starts turning into thick, irregular bundles compared to what would be seen in healthy tissue.
Sources: en.wikipedia.org
The duration of estradiol esters in oil solution by intramuscular injection is dose-dependent. With estradiol valerate, it is reported that a dose of 5 mg has a duration of 7 to 8 days, 10 mg a duration of 10 to 14 days, 40 mg a duration of 2 to 3 weeks, and 100 mg a duration of 3 to 4 weeks. High doses of estradiol valerate, such as 40 mg per week, can achieve pregnancy levels of estradiol. A study of pseudopregnancy with intramuscular injections of 40 mg/week estradiol valerate and 250 mg/week hydroxyprogesterone caproate observed estradiol levels of about 2,500 to 3,000 pg/mL.
What distinguishes the androgen backdoor from the classical pathway is whether 5α-reduction initiates or terminates the pathway. In the backdoor pathway, 5α-reduction of progesterone (P4) or 17α-hydroxyprogesterone (17OHP) occurs at or near the beginning of the pathway respectively. Conversely, in the classical pathway, 5α-reduction is the final step, where testosterone is converted into dihydrotestosterone (DHT). The backdoor pathway splits into two subpathways at P4, proceeding through either 17OHP or 5α-DHP before merging again at 5α-Pdiol. The biosynthetic intermediate 5α-Pdiol in turn is converted into DHT in two chemical steps.
The NO can then contribute to two suggested pathways. Under typical conditions, nitric oxide (NO) interacts non-covalently with the heme and copper (Cu) subunits of CCO, competing with oxygen molecules and inhibiting cellular respiration, leading to reduced production of adenosine triphosphate (ATP). Low energy light can revise the mitochondrial inhibition of cellular respiration by photodissociating of NO from CCO, and thereby increasing ATP synthesis. The second pathway proposes that released nitric oxide (NO) will boost Cytochrome c Oxidase (CCO) activity, as an enzyme nitrite reductase. This mechanism includes the transfer of electrons to oxygen molecules, resulting in the production of water and reactive oxygen species (ROS). The ROS then activates enzymes necessary for producing vital cellular components like nucleic acids and proteins. LED therapy may also increase ROS, which may activate transcription factors that manage genes important for cell growth, cytokine production, and making growth factors for cell repair and proliferation.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.